Showing results (171-180 of 215) with videos related to
Sort By:
Pageof 22
World Neurosurgery|September 21, 2020
Stereotactic Brain Biopsy Hemorrhage Risk Factors and Implications for Postoperative Care at a Single Institution: An Argument For Postoperative ImagingAriana S Barkley, Liam T Sullivan, Alec W Gibson, et al.Neurosurgery|December 22, 2018
Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 YearsChibawanye I Ene, Meghan W Macomber, Jason K Barber, et al.Journal of Neurosurgery|March 21, 2007
Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomasVinay Gupta, Yuzhuang S Su, Christian G Samuelson, et al.Epilepsia|July 12, 2012
Cortical stimulation mapping and Wada results demonstrate a normal variant of right hemisphere language organizationDaniel L Drane, Jenny Roraback-Carson, Adam O Hebb, et al.Head & Neck|February 14, 2006
Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expressionRobert C Rostomily, Maria Elias, Mei Deng, et al.Anticancer Research|May 7, 2013
Prolonged survival of patients with breast cancer-related leptomeningeal metastasesEmilie Le Rhun, Sophie Taillibert, Fahed Zairi, et al.International Journal of Radiation Oncology, Biology, Physics|October 26, 2005
[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failureJames G Douglas, Keith J Stelzer, David A Mankoff, et al.Neuro-Oncology|July 10, 2010
A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastomaMyrna R Rosenfeld, Marc C Chamberlain, Stuart A Grossman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapyMichael S Bobola, Mary J Emond, A Blank, et al.Cancer|July 29, 2010
A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomasJeffrey J Raizer, Sean Grimm, Marc C Chamberlain, et al.Pageof 22